Table 3.
Distribution of relevant demographic and clinical characteristics by subtypes in the TCGA-PRAD cohort.
| Subtype 1 | Subtype 2 | Subtype 3 | Subtype 4 | p-value | ||
|---|---|---|---|---|---|---|
| Age | Median (25%, 75%) | 60 (56, 66) | 60 (55, 65) | 64 (59, 68) | 64 (58, 67) | 1.02×10−5 |
| Race | ||||||
| Caucasian | 112 (82%) | 131 (92%) | 86 (79%) | 76 (88%) | ||
| African American | 19 (14%) | 9 (6%) | 21 (19%) | 9 (10%) | 0.037 | |
| Asian | 6 (4%) | 3 (2%) | 2 (2%) | 1 (1%) | ||
| Gleason Score | ||||||
| <= 6 | 19 (14%) | 15 (10%) | 3 (3%) | 4 (5%) | ||
| 7 (3+4) | 49 (36%) | 56 (39%) | 21 (19%) | 20 (23%) | 8.32×10−5 | |
| 7 (4+3) | 23 (17%) | 23 (16%) | 28 (26%) | 23 (27%) | ||
| 8–10 | 46 (34%) | 49 (34%) | 57 (52%) | 39 (45%) | ||
| PSA (ng/mL) at diagnosis | ||||||
| <4 | 18 (13%) | 19 (13%) | 6 (6%) | 7 (8%) | ||
| 4–10 | 76 (55%) | 88 (62%) | 55 (50%) | 45 (52%) | ||
| 10–20 | 31 (23%) | 25 (17%) | 23 (21%) | 14 (16%) | 7.38×10−3 | |
| ≥20 | 11 (8%) | 7 (5%) | 19 (17%) | 16 (19%) | ||
| Missing | 1 (1%) | 4 (3%) | 6 (6%) | 4 (5%) | ||
| Stage | ||||||
| Local/T2 | 60 (44%) | 60 (42%) | 29 (27%) | 29 (34%) | ||
| Regional/T3 | 54 (39%) | 59 (41%) | 62 (57%) | 36 (42%) | 0.024 | |
| T4/N1 | 21 (15%) | 22 (15%) | 16 (15%) | 21 (24%) | ||
| Missing | 2 (1%) | 2 (1%) | 2 (2%) | 0 (0%) | ||
| TMPRSS2-ERG gene fusion | ||||||
| No fusion | 119 (87%) | 17 (12%) | 75 (69%) | 81 (94%) | 5.9×10−49 | |
| Fusion | 18 (13%) | 126 (88%) | 34 (31%) | 5 (6%) | ||